Antiangiogenic therapies for advanced hepatocellular carcinoma

Oncologist

Volumn 18, Issue 4, 2013, Pages 430-438

  Sampat, Keeran R ^a   O'Neil, Bert ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; FGF; Hepatocellular carcinoma; Vascular endothelial growth factor; VEGF

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CISPLATIN; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; GOLVATINIB; LINIFANIB; MAPATUMUMAB; NINTEDANIB; ORANTINIB; OXALIPLATIN; PLACEBO; PRAVASTATIN; RAMUCIRUMAB; SORAFENIB; SUNITINIB; THALIDOMIDE; TIGATUZUMAB; VANDETANIB;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DIARRHEA; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LASER SURGERY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877037038     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0388     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
4. Nathan H, Schulick RD, Choti MA et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249: 799-805.
5. Thomas MB, Jaffe D, Choti MM. et al. Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994-4005.
6. Ferna ́ndez M, Semela D, Bruix J et al. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
7. Dhar DK, Naora H, Yamanoi A et al. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/ Tie pathway. Anticancer Res 2002; 22: 379-386.
8. Tseng PL, Tai MH, Huang CC et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008; 98: 349-357.
9. Park YN, Kim YB, Yang KM et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-1065.
10. Conway EM, Collen D, Carmeliet P. Molecular mechanismsof blood vessel growth. Cardiovasc Res 2001; 49: 507-521.
11. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483-489.
12. Yoshiji H, Kuriyama S, Yoshii J et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-842.
13. Nexavar [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, 2011.
14. Huynh H, Ngo VC, Koong HN et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009; 13: 2673-2683.
15. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. NEngl JMed 2008; 359: 378-390.
16. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
17. Marrero JA, Lencioni R, KudoMet al. Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29(suppl 15): 4001.
18. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160.
19. Shim JH, Park JW, Kim JH et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008; 99: 2037-2044.
20. Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double- blind SPACE trial. ASCO Meeting Abstracts 2012; 30: LBA154.
21. Mendel DB, Laird AD, Xin X et al. In vivo antitumoractivity ofSU11248,anovel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
22. Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359-1370.
23. Cheng A, Kang Y, Lin D et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29(suppl 15): Abstract 4000.
24. Avastin [package insert]. South San Francisco, CA: Genetech Inc 2009.
25. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinicalandbiologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
26. Sun W, Sohal D, Haller DG et al. Phase 2 trial of bevacizumab, capecitabine,andoxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011; 117: 3187-3192.
27. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as firstline therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102: 981-986.
28. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903.
29. Vlachogiannakos J, Goulis J, Patch D et al. Primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther 2000; 14: 851-860.
30. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
31. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in flk-1-deficient mice. Nature 1995; 376: 62-66.
32. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34: 1785-1788.
33. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787.
34. Zhu AX, Finn RS, Mulcahy MF et al. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010; 28(suppl 15): 4083.
35. Wong CI, Koh TS, Soo R et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009; 27: 4718-4726.
36. Toh H, Chen P, Carr BI et al. Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010; 28(suppl 15): 4038.
37. Alberts SR, Fitch TR, Kim GP et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial. Am J Clin Oncol 2012; 35: 329-333.
38. Huynh H, Ngo VC, Fargnoli J et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146-6153.
39. Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor- 1 kinases. Mol Cancer Ther 2010; 9: 369-378.
40. Tovar V, Cornella H, Villanueva A et al. FGF signaling dysregulation in HCC and role in the development of acquired resistance to anti-angiogenic therapies. Paper presented at: 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 4- 8, 2011; San Francisco, CA.
41. Park JW, Finn RS, Kim JS et al. Phase II, openlabel study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983.
42. Finn RS, Kang YK, Mulcahy M et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-2098.
43. Llovet JM, Decaens T, Raoul J-L et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC)whofailed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. J Hepatol 2012; 56(suppl 2): S549.
44. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
45. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
46. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117: 5094-5102.
47. Kanai F, Yoshida H, Tateishi R et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67: 315-324.
48. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
49. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
50. Lieu C, Heymach J, Overman M et al. Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-6139.
51. Casanovas O, Hicklin DJ, Bergers G et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
52. Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28: 453-459.
53. Gauglhofer C, Sagmeister S, Schrottmaier W., et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011; 53: 854-864.
54. Cascone T, Herynk MH, Xu L et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011; 121: 1313-1328.
55. Rapisarda A, Hollingshead M, Uranchimeg B et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8: 1867-1877.
56. Yuan P, Wang L, Wei D et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effectsonhumanpancreatic cancer. Cancer 2007; 110: 2682-2690.
57. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
58. Huang H, Bhat A, Woodnutt G et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
59. Lee JH, Park JY, Kim do Y et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011; 31: 1144-1149.
60. Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2012; 58: 169-177.